EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

A REVIEW OF COVID-19 TREATMENT

Mohamed Ashraf P. T.*

ABSTRACT

This review mainly focusing on antivirals and drugs with immune-modulatory, anti-inflammatory properties, against COVID-19, their pharmacological features and achievement in term of patients' clinical outcomes. The global pandemic of novel corona virus disease 2019 (Covid-19) caused by SARS-CoV-2 began in Wuhan, China, in December 2019, and has since spread worldwide. At the time of this review, COVID-19 has been diagnosed more than 6,485,526 cases and 386,704 death. A large number of antiviral agents, including lopinavir/ritonavir, favipiravir, remdesivir, many of which are used for the treatment of hepatitis, human immunodeficiency virus (HIV) and flu symptoms are currently using as off-label for the worldwide patients. The viral lifecycle, viral entry, and immune regulation pathway providing potential targets for drug therapy.

Keywords: Covid-19, cytokine storm, ARDS, Favipiravir, Remdesivir, Tocilizumab.

[Full Text Article] [Download Certificate]